Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter C Enzinger

Showing results (31-40 of 91) with videos related to

Pageof 10
Sort By:
Digestive Diseases and Sciences|January 18, 2006
A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinomaPeter C Enzinger, Matthew H Kulke, Jeffrey W Clark, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2006
Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancerJeffrey A Meyerhardt, Andrew X Zhu, Peter C Enzinger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumorsMatthew H Kulke, Jason L Hornick, Christine Frauenhoffer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2012
Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumorsJennifer A Chan, Keith Stuart, Craig C Earle, et al.
Cancer|October 13, 2006
Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumorsDavid P Ryan, Leonard J Appleman, Thomas Lynch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2007
Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancerMatthew H Kulke, Lawrence S Blaszkowsky, David P Ryan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancerBrian M Wolpin, Aram F Hezel, Thomas Abrams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2016
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction CancersPeter C Enzinger, Barbara Ann Burtness, Donna Niedzwiecki, et al.
Cancer|June 23, 2007
Phase 2 study of cetuximab in patients with advanced hepatocellular carcinomaAndrew X Zhu, Keith Stuart, Lawrence S Blaszkowsky, et al.
BMJ Open Sport & Exercise Medicine|June 20, 2022
Physical activity in older adults with metastatic gastrointestinal cancer: a pilot and feasibility studyJustin C Brown, Elizabeth Brighton, Nancy Campbell, et al.
Pageof 10

Showing results (31-40 of 91) with videos related to

Sort By:
Pageof 10
Digestive Diseases and Sciences|January 18, 2006
A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinomaPeter C Enzinger, Matthew H Kulke, Jeffrey W Clark, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2006
Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancerJeffrey A Meyerhardt, Andrew X Zhu, Peter C Enzinger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumorsMatthew H Kulke, Jason L Hornick, Christine Frauenhoffer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2012
Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumorsJennifer A Chan, Keith Stuart, Craig C Earle, et al.
Cancer|October 13, 2006
Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumorsDavid P Ryan, Leonard J Appleman, Thomas Lynch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2007
Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancerMatthew H Kulke, Lawrence S Blaszkowsky, David P Ryan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancerBrian M Wolpin, Aram F Hezel, Thomas Abrams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2016
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction CancersPeter C Enzinger, Barbara Ann Burtness, Donna Niedzwiecki, et al.
Cancer|June 23, 2007
Phase 2 study of cetuximab in patients with advanced hepatocellular carcinomaAndrew X Zhu, Keith Stuart, Lawrence S Blaszkowsky, et al.
BMJ Open Sport & Exercise Medicine|June 20, 2022
Physical activity in older adults with metastatic gastrointestinal cancer: a pilot and feasibility studyJustin C Brown, Elizabeth Brighton, Nancy Campbell, et al.
Pageof 10